HeartSciences (NASDAQ:HSCS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of HeartSciences (NASDAQ:HSCS) to a sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

HeartSciences Stock Performance

Shares of HeartSciences stock opened at $3.54 on Friday. HeartSciences has a fifty-two week low of $1.63 and a fifty-two week high of $4.35. The firm has a 50-day simple moving average of $2.69 and a two-hundred day simple moving average of $2.39. The company has a market cap of $13.81 million, a P/E ratio of -0.90 and a beta of 1.85.

HeartSciences (NASDAQ:HSCS) last issued its quarterly earnings data on Tuesday, September 15th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.14). The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.10 million. Equities research analysts forecast that HeartSciences will post -3.04 EPS for the current year.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non?invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high?fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high?frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.